Mechanism of Modified Taohe Chengqitang in Treating Type 2 Diabetes Mellitus Based on Network Pharmacology

Qiang XU; Hong-yu HUANG; Mei-si ZHENG; Zhang-zhi ZHU

doi:10.13422/j.cnki.syfjx.20192141

您当前的位置：

首页 >

文章列表页 >

Mechanism of Modified Taohe Chengqitang in Treating Type 2 Diabetes Mellitus Based on Network Pharmacology

Data Mining | 更新时间：2021-02-09

- Mechanism of Modified Taohe Chengqitang in Treating Type 2 Diabetes Mellitus Based on Network Pharmacology
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 25, Issue 22, Pages: 166-174(2019)
- 作者机构：
  
  1.广州中医药大学　第一临床医学院，广州　 510006；
  2.广州中医药大学　第一附属医院，广州　 510405
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20192141
  CLC： R2-0; R289; R587.1
- Published：20 November 2019，
  
  Published Online：18 July 2019，
  
  Received：08 June 2019，
- 稿件说明：
扫描看全文
Qiang XU, Hong-yu HUANG, Mei-si ZHENG, et al. Mechanism of Modified Taohe Chengqitang in Treating Type 2 Diabetes Mellitus Based on Network Pharmacology. [J]. Chinese Journal of Experimental Traditional Medical Formulae 25(22):166-174(2019)
DOI：

Qiang XU, Hong-yu HUANG, Mei-si ZHENG, et al. Mechanism of Modified Taohe Chengqitang in Treating Type 2 Diabetes Mellitus Based on Network Pharmacology. [J]. Chinese Journal of Experimental Traditional Medical Formulae 25(22):166-174(2019) DOI： 10.13422/j.cnki.syfjx.20192141.

摘要

目的：

基于网络药理学方法研究加味桃核承气汤干预2型糖尿病的潜在作用靶点。

方法：

基于TCMSP数据库及Uniprot数据库筛选出加味桃核承气汤有效成分及靶点基因。通过GeneCards数据库及OMIM数据库筛选出2型糖尿病的疾病靶点基因，并用Cytoscape软件构建“活性成分-靶点”相互作用网络图。将有效成分靶标与疾病靶标上传到STRING数据库，构建蛋白互作网络图(PPI)，并计算其特征值，使用R语言对得到的PPI进行核心基因的筛选。最后，运用R语言对关键靶点进行基因本体(GO)富集分析和京都基因与基因组百科全书(KEGG)通路富集分析。

结果：

预测得到加味桃核承气汤治疗2型糖尿病的有效成分155个及共作有效靶点106个。有效成分中度值较高的为槲皮素(quercetin)，山柰酚(kaempferol)及异鼠李素(isorhamnetin)，作用靶点中度值较高的为雌激素受体(ESR1)，过氧化物酶体增殖剂激活受体

(PPARG)与雄激素受体(AR)。PPI网络中核心基因为表皮生长因子受体(EGFR)及ESR1等；GO富集分析显示会影响基因的转录、核受体活性及激素的受体结合、神经递质等；KEGG通路富集分析显示流体剪切应力和动脉粥样硬化通路为显著性最高的通路，其次为晚期糖基化终末产物及其受体通路。

结论：

通过网络药理学的方法预测加味桃核承气汤防治2型糖尿病的关键作用靶点及相关通路，结果提示此方剂具有多靶点、多通路等复杂机制，不仅表明加味桃核承气汤具有降糖的作用，而且其还具有抗炎、改善胰岛素抵抗、调节脂代谢等生物学功能。

Abstract

Objective:

To study the potential therapeutic targets of modified Taohe Chengqitang for type 2 diabetes mellitus based on network pharmacology.

Method:

Based on TCMSP database and Uniprot database

the active constituents and target genes of flavored modified Taohe Chengqitang were screened.Target genes of type 2 diabetes were screened by gene cards database and OMIM database

and Cytoscape software was used to construct " active component-target" interaction network diagram.The active component targets and disease targets were uploaded to the STRING database

the protein interaction network map (PPI) was constructed

and the characteristic values were calculated

and core genes were screened by using R language.Finally

R language was used to analyze gene ontology (GO) enrichment and kyoto encyclopedia of genes and genome (KEGG) pathway enrichment of key targets.

Result:

The 155 active components and 106 effective targets of modified Taohe Chengqitangin the treatment of type 2 diabetes were predicted.Quercetin

kaempferol and isorhamnetin were the most effective components

while estrogen receptor alpha (ESR1)

peroxidosomal hyperplasia activates receptor gamma (PPARG) and androgen receptor (AR) were the most effective components.Core genes in PPI network areepidermal growth factor receptor (EGFR)and ESR1

etc.GO enrichment analysis shows that it can affect gene transcription

nuclear receptor activity

hormone receptor binding

neurotransmitter

etc.Enrichment analysis of KEGG pathway showed that fluid shear stress and atherosclerosis pathways were the most significant pathways

followed by advanced glycation end products-receptor for AGE (AGE-RAGE) pathway.

Conclusion:

Predicted by the method of network pharmacology modified Taohe Chengqitang key targets for prevention and treatment of type 2 diabetes and related pathways

results suggest the recipe has multiple targets

multiple pathways

such as complex mechanism

not only show that modified Taohe Chengqitang has hypoglycemic effect

but it also has anti-inflammatory

improve insulin resistance

regulate lipid metabolism

and biological functions.

关键词

加味桃核承气汤2型糖尿病网络药理学潜在靶点

Keywords

modified Taohe Chengqitangtype 2 diabetesnetwork pharmacologypotential targets

references

沈洁，周珊珊，万晓刚．黄连对2型糖尿病大鼠胰腺内质网应激PERK/ATF4/CHOP信号通路的影响[J]．中国实验方剂学杂志，2019，25(16)：50-55．

Tadic M, Cuspidi C. Type 2 diabetes mellitus and atrial fibrillation: from mechanisms to clinical practice [J].Arch Cardiovasc Dis, 2015, 108(4): 269-276.

江丹，吴伟，林明欣，等．降糖三黄片对早期糖尿病肾病大鼠肾组织TGF-β1/Smad1信号通路的影响[J]．世界中医药，2014，9(8)：1067-1072．

陈云，李赛美，王保华．降糖三黄片对糖尿病肾病大鼠肾组织蛋白激酶C和转化生长因子β1的影响[J]．中医杂志，2012，53(8)：689-692．

熊曼琪，梁柳文，林安钟，等．加味桃核承气汤治疗Ⅱ型糖尿病的临床和实验研究[J]．中国中西医结合杂志，1992，20(2)：74-75．

储全根，李赛美，莫伟，等．加味桃核承气汤及其不同提取物对糖尿病大鼠心肌细胞GluT4 mRNA表达的影响[J]．中国中医基础医学杂志，2006，12(12)：912-914．

李赛美，凌家杰，王志高．加味桃核承气汤及其拆方对糖尿病血管病变的体外作用观察[J]．广州中医药大学学报，2008，25(1)：51-53．

古玉梅，朱章志，许帅，等．加味桃核承气汤对糖尿病大鼠血糖、血脂及大血管病变的影响[J]．中药新药与临床药理，2017，28(5)：583-587．

熊曼琪，苗理平．加味桃核承气汤对糖尿病鼠肾超微结构的影响[J]．中国医药学报，1990，21(5)：25-27．

李静，葛超，韩莲莲，等．加味桃核承气汤对STZ糖尿病大鼠肝、肾和心组织的抗氧化保护作用[J]．安徽农业科学，2013，41(30)：12052-12054，12058．

徐婷，麦葭沂，向俊，等．“黄芪-当归”药对主要活性成分的网络药理学研究[J]．中药材，2017，40(9)：2195-2201．

严诗楷，赵静，窦圣姗，等．基于系统生物学与网络生物学的现代中药复方研究体系[J]．中国天然药物，2009，7(4)：249-259．

马纳，李亚静，范吉平．槲皮素药理作用研究进展[J]．辽宁中医药大学学报，2018，20(8)：221-224．

张雅雯，邵东燕，师俊玲，等．山奈酚生物功能研究进展[J]．生命科学，2017，29(4)：400-405．

滕丹，栾新尧．异鼠李素的药效学研究进展[J]．中医药临床杂志，2016，28(4)：593-596．

葛凌，蔡亚军，王章达．槲皮素对2型糖尿病大鼠胰岛素抵抗的改善作用及FGF21/MAPK信号通路的影响[J]．中国药师，2019，22(3)：418-421．

刘贵波，刘跃光，孙成，等．山奈酚对2型糖尿病大鼠糖脂代谢及胰岛素抵抗的影响[J]．实用临床医药杂志，2012，16(9)：1-3．

吴巧敏，金雅美，倪海祥．山柰酚对2型糖尿病大鼠慢性并发症相关因子的影响[J]．中草药，2015，46(12)：1806-1809．

白跳，迟丽屹，高宇勤，等．异鼠李素对糖尿病大鼠心肌纤维化的干预作用[J]．新疆医科大学学报，2018，41(7)：865-869．

谭琪明，胡丹，何珺．沙棘中异鼠李素降血糖活性研究[J]．亚太传统医药，2016，12(15)：13-15．

段炼，李会军，闻晓东，等．黄芪治疗糖尿病研究进展[J]．中国新药杂志，2013，22(7)：776-781，792．

张明发，沈雅琴．甘草及其有效成分的抗糖尿病药理作用的研究进展[J]．抗感染药学，2015，12(1)：1-5．

郭艳娟，赵楠楠，邹歌，等．妊娠期糖尿病患者血清miR-222和雌激素受体-α表达的临床意义[J]．中国计划生育学杂志，2018，26(11)：1086-1090．

马丽媛，李超，王伟伟．雌激素受体β基因AluI、RsaI位点多态性与妊娠期糖尿病易感性研究[J]．国际检验医学杂志，2019，40(9)：1062-1065．

贺小威，韩丽炘，赵越．雄激素受体及其辅调节因子在肥胖及胰岛素抵抗中作用的研究进展[J]．生命科学，2015，27(4)：453-461．

林小晶．Chemerin在有氧运动改善肥胖和2型糖尿病大鼠糖脂代谢中的作用及PPARγ相关机制[D]．上海：上海体育学院，2017．

郭莉霞，殷菲，刘建辉．表皮生长因子受体及其配体与胰腺β细胞[J]．生物医学工程学杂志，2011，28(1)：203-207．

王全顺，张国山，刘洁，等．转化生长因子与糖尿病肾病发病机制研究进展[J]．临床医药文献电子杂志，2017，4(43)：8408．

郭宜晨，鲁亚静，钟伟传，等．2型糖尿病患者外周血miRNA表达谱差异研究[J]．现代检验医学杂志，2018，33(6)：5-8．

王水良，傅继梁．核受体的研究进展[J]．遗传学报，2004，31(4)：420-429．

李芬．小檗碱改善胰岛素抵抗作用分子机制的研究[D]．武汉：华中科技大学，2016．

吴珺，鲁一兵，刘超．Toll样受体和糖尿病[J]．国际内分泌代谢杂志，2008，28(2)：116-118．

Harada C, Harada T, Mitamura Y, et al. Diverse NF-kappaB expression in epiretinal membranes after human diabetic retinopathy and proliferative vitreoretinopathy [J].Mol Vis, 2004, 10(4/5): 31-36.

Ortis F. Induction of nuclear factor-kappaB and its downstream genes by TNF-alpha and IL-1beta has a pro-apoptotic role in pancreatic beta cells [J].Diabetologia, 2008, 51(7): 13-25.

Sriwijitkamol A, Christ-Roberts C, Berria R, et al. Reduced skeletal muscle inhibitor of kappaB beta content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training [J].Diabetes, 2006, 55(3): 760-767.

Yamagishi S I. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes [J].Exp Gerontol, 2011, 46(4): 217-224.

许帅．基于AGEs-RAGE加味桃核承气汤防治T2DM大血管病变大鼠的实验研究[D]．广州：广州中医药大学，2017．

邓小凤．基于NF-κB通路加味桃核承气汤及其化裁方防治糖尿病大血管病变的实验研究[D]．广州：广州中医药大学，2016．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of Potential Active Ingredients and Mechanism of Baihu Jia Renshentang in Treatment of Obesity Complicated with Type 2 Diabetes Mellitus

Mechanism of Zishen Qinggan Prescription in Improving Glucose and Lipid Metabolism in Type 2 Diabetes Based on Transcriptomics

Mechanism of Modified Taohe Chengqitang in Treating Diabetic Gastroparesis Based on Network Pharmacology

Related Author

TAN Danni

XIANG Qin

YU Yunfeng

YU Rong

WANG Jingcun

TIAN Chunyu

ZHANG Fan

LA Xiaojin

Related Institution

School of Traditional Chinese Medicine，Hunan University of Chinese Medicine

North China University of Science and Technology

Hebei Key Laboratory of Integrated Traditional Chinese and Western Medicine for Diabetes and Its Complications

Tangshan Key Laboratory of Chinese Medicine Pharmacology

Shenzhen Bao' an Hospital of Traditional Chinese Medicine

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰